Vaccinex Reports Third Quarter 2018 Financial Results and Provides Corporate Update
November 13, 2018 07:58 ET
|
Vaccinex, Inc.
Lead candidate pepinemab (VX15) being evaluated in three ongoing clinical trials in cancer and Huntington’s Disease Enrollment in CLASSICAL Lung Cancer trial and Cohort B of the SIGNAL Huntington’s...
Vaccinex, Inc. Presents Overview of the Clinical Development of VX15 (pepinemab) for the Potential Treatment of Huntington’s Disease at the Huntington Study Group’s 2018 Annual Meeting
November 12, 2018 08:30 ET
|
Vaccinex, Inc.
Presentation and Poster Include Previously Announced Results of Cohort A of SIGNAL Trial ROCHESTER, N.Y., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage...
Vaccinex, Inc. to Present Data on Its Semaphorin 4D Monoclonal Antibody Programs at Two Conferences Focused on Cancer Immunotherapy and Huntington’s Disease
November 06, 2018 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. to Participate on a Panel and Meet with Investors at the BTIG Healthcare Conference October 25, 2018
October 23, 2018 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. Presents Preliminary Data on Its Anti-Semaphorin 4D Monocolonal Antibody Technology at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
October 02, 2018 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. to Participate in Podium and Poster Sessions at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
September 27, 2018 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
Vaccinex, Inc. to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 25, 2018 08:30 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to...
Vaccinex Announces Pricing of Initial Public Offering
August 09, 2018 09:08 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat...
Vaccinex, Inc. to Host Key Opinion Leader Luncheon on Huntington’s Disease
January 30, 2018 11:14 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal...
Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
January 08, 2018 13:10 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat...